Kamada: Rises on distribution deals for three biosimilars

Kamada

13/01/2021 12:48

** U.S.-listed shares of Israel-based drug developer
 KMDA.TA ,  KMDA.O  rise 1.8% to $7.17 premarket
    ** Co enters into agreements with two undisclosed
pharmaceutical companies to commercialize three biosimilar
product candidates in Israel (https://refini.tv/3oFModt)
    * Biosimilars are cheaper copies of branded drugs and
although they cannot be exactly replicated, studies testing them
seek to show their effect is equivalent to the reference drug
    ** Products are expected to be launched, subject approval
from Israel's health ministry, between 2022 and 2024
    ** KMDA expects maximum annual sales generated by
distribution of these three products to be in the range of $5
mln to $7 mln 
    ** KMDA's U.S.-listed shares up 8.6% this year, as of last
close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))